Literature DB >> 2959405

Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue.

C P West1, D T Baird.   

Abstract

A long-acting LHRH agonist, Zoladex depot 3.6 mg, was administered as a monthly s.c. injection to seven premenopausal volunteers for a maximum of 6 months, starting in the luteal phase of the cycle. Transient stimulation of gonadotrophin release was observed 24 h after the initial depot, followed by sustained suppression of plasma LH, while FSH levels returned to the normal range. Plasma oestradiol concentrations fell to early follicular phase values within 14 d. Twice-weekly monitoring of urinary oestrone-3-glucuronide and pregnanediol demonstrated inhibition of ovulation and almost complete suppression of ovarian follicular activity throughout therapy. All the subjects became amenorrhoeic. Mean plasma testosterone concentrations were also significantly reduced while androstenedione remained within the pretreatment range. SHBG concentrations were not significantly reduced. After cessation of therapy, postovulatory menstruation occurred within 80 d of administration of the last depot.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959405     DOI: 10.1111/j.1365-2265.1987.tb00779.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women.

Authors:  Susan M Cheer; Greg L Plosker; Dene Simpson; Antona J Wagstaff
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions.

Authors:  Matt T Bianchi; Semmie Kim; Thania Galvan; David P White; Hadine Joffe
Journal:  J Clin Sleep Med       Date:  2016-07-15       Impact factor: 4.062

3.  Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.

Authors:  Adnan Aydiner; Leyla Kilic; Ibrahim Yildiz; Serkan Keskin; Fatma Sen; Seden Kucucuk; Hasan Karanlik; Mahmut Muslumanoglu; Abdullah Igci
Journal:  Med Oncol       Date:  2012-12-29       Impact factor: 3.064

Review 4.  Current drug therapy recommendations for the treatment of endometriosis.

Authors:  A Bergqvist
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 5.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 6.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

7.  Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol.

Authors:  Hadine Joffe; David P White; Sybil L Crawford; Kristin E McCurnin; Nicole Economou; Stephanie Connors; Janet E Hall
Journal:  Menopause       Date:  2013-09       Impact factor: 2.953

8.  A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep.

Authors:  Hadine Joffe; Sybil Crawford; Nicole Economou; Semmie Kim; Susan Regan; Janet E Hall; David White
Journal:  Sleep       Date:  2013-12-01       Impact factor: 5.849

9.  Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.

Authors:  W Jonat
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.